Once-daily therapy: less is more. - Wikidata - awgldk - TriplyDB

Once-daily therapy: less is more.

Once-daily therapy: less is more.

http://www.wikidata.org/entity/Q35583692

about

Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children.

P2860

Q36607380-73F493FE-D326-473F-99AF-D4A284F19592 Q36688943-D2BD6205-9ADF-4CA3-872C-E432D73242E5 Q39051618-C06DB6FC-A47A-4C6A-BEF0-CE0840063637

P2860

Once-daily therapy: less is more.

http://www.wikidata.org/entity/Q35583692

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Once-daily therapy: less is more.

@ast

Once-daily therapy: less is more.

@en

type

label

Once-daily therapy: less is more.

@ast

Once-daily therapy: less is more.

@en

prefLabel

Once-daily therapy: less is more.

@ast

Once-daily therapy: less is more.

@en

P1433

Q35583692-DFD14ACD-23D0-4F71-95A7-FF3375CB1EEF

P1476

Q35583692-092BEA7A-A88B-4A6C-96CA-5B58DD757D7E

P2093

Q35583692-15AF7939-9BC0-4E37-A486-B000B9DE3207

P2860

Q35583692-1178C3FF-9D1B-4A29-B4F5-72BF23986311

Q35583692-384BCC88-39CC-47BC-B142-66C6095FB2DF

Q35583692-4C092BF0-2892-4737-A1D2-E862C58A5566

P304

Q35583692-A919BCCE-E798-4A9F-8E0D-C20D5064C54C

P31

Q35583692-FB1A0DEA-85B0-4DCE-B08B-BC520947838B

P356

Q35583692-A225F8DC-69E6-40E1-9226-06211A5BF1E0

P478

Q35583692-4A43F370-25AA-4422-A24B-BD4552C5B296

P577

Q35583692-43EAFA4E-7698-4B04-874B-C4154B605C79

P698

Q35583692-EA2BD3B6-AA8B-437F-B43C-D53E321747BA

P356

095646203322491815

P1433

International Journal of STD & AIDS

P1476

Once-daily therapy: less is more.

@en

P2093

Moyle G

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review of the associations between dose regimens and medication compliance.

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.

P304

1-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1258/095646203322491815

http://www.w3.org/2001/XMLSchema#string

P478

14 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14617397

http://www.w3.org/2001/XMLSchema#string